Author + information
- Ioanna Xanthopoulou,
- Katerina Stavrou,
- Eleni Mavronasiou,
- Vasileios Gizas,
- Angelos Perperis,
- Michalis Hamilos,
- Vlassis Pyrgakis,
- Filippos Triposkiadis,
- Ioannis Goudevenos and
- Dimitrios Alexopoulos
Few comparative data exist on in-hospital bleeding events with the concurrent use of clopidogrel, prasugrel and ticagrelor in real-life patients with ACS undergoing percutaneous coronary intervention (PCI).
We performed detailed recording of bleeding events (Bleeding Academic Research Consortium -BARC classification) in the context of a prospective multi-centre, observational study of antiplatelet treatment patterns in ACS patients subjected to PCI in Greece.
From January to August 2012, out of 875 patients registered, 333 subjected to in-hospital P2Y12-inhibitor switching and 2 died without receiving any P2Y12-inhibitor, leaving 540 patients to be included in analysis (81.9% men, 23.1% diabetics, with a mean age of 63.1±12.6 years). In total, 23(4.3%), 13(2.4%) and 12(2.2%) patients presented an in-hospital BARC1, BARC2 and BARC3 bleeding event respectively. No fatal bleeding event occurred. In multivariate (logistic regression) analysis, age≥75 years, prior bleeding and ticagrelor or prasugrel use emerged as independent risk factors for any BARC bleeding event (Figure)
In a real-world PCI-treated ACS population, prasugrel and ticagrelor use is associated with an increased risk of low to moderate severity bleeding events.
Moderated Poster Contributions
Poster Sessions, Expo North
Sunday, March 10, 2013, 9:45 a.m.-10:30 a.m.
Session Title: Bleeding and ACS: Predicting Risk and Measuring Impact
Abstract Category: 1. Acute Coronary Syndromes: Clinical
Presentation Number: 1215M-197
- 2013 American College of Cardiology Foundation